The BSX Gamble: A Tangled Web of Risk and Reward

Boston Scientific’s (BSX) recent struggles have sent its stock plummeting to nearly $45 a share, a 58% decline from its 52-week peak. Investors are scrambling to make sense of the situation, with some advocating for selling cash-secured put options as a way to generate immediate income while locking in an even deeper entry point.

The numbers appear appealing: selling a put option on BSX expiring in 2027 with a strike price of $30 can yield roughly $135 in premium per contract and earn about 8.3% total cash-secured return. However, this calculation assumes investors are comfortable holding onto the stock through a turnaround, particularly given the operational headwinds facing two core growth drivers – WATCHMAN and electrophysiology.

These businesses are not as stable as they once seemed. New clinical evidence has altered referral patterns for WATCHMAN in the US market, leading to a sharp slowdown in sales. Meanwhile, Boston Scientific’s share in the US electrophysiology market has shrunk more than expected, and the company now expects flat global growth for the second half of 2026 – despite international sales increasing by 23% in the June quarter.

A significant portion of BSX revenue comes from businesses other than WATCHMAN and electrophysiology, which management projects will continue to grow at a rate of around 6% in the second half of 2026. However, the stock’s decline is largely due to these two struggling segments.

Selling cash-secured put options on BSX may not be as straightforward as it seems. While it allows investors to generate income and lock in an entry point at a discounted price, it also exposes them to significant risk if the company continues to struggle. As one investor noted, “if the shares do fall that far, everything turns on what you would own.”

BSX’s stock performance is a microcosm of the broader trends in the medical device industry: companies face increasing regulatory scrutiny, rising competition from low-cost producers, and growing pressure to deliver consistent growth. In this environment, can investors truly afford to take on additional risk by holding onto a struggling stock?

Boston Scientific has a history of surprising investors, often in ways that are difficult to anticipate. The potential consequences of buying BSX at its current price – or worse still, holding onto it through a downturn – are far more nuanced than any simple calculation can capture.

Ultimately, the decision to sell cash-secured put options on BSX is a personal one, requiring careful consideration of an investor’s individual risk tolerance and long-term goals. While the numbers may look appealing, they should not be taken at face value. Investors would do well to dig deeper into the company’s fundamentals, industry trends, and potential risks – before making any decisions that could have far-reaching consequences for their portfolios.